Have a personal or library account? Click to login
Cardiovascular and Metabolic Comorbidities in Patients with Plaque-Type Psoriasis Never Treated with Systemic Antipsoriatic Drugs: a Case-Control Study Cover

Cardiovascular and Metabolic Comorbidities in Patients with Plaque-Type Psoriasis Never Treated with Systemic Antipsoriatic Drugs: a Case-Control Study

Open Access
|Oct 2013

References

  1. 1. Parisi R, Symmons D, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133(2):377-85.10.1038/jid.2012.339
  2. 2. Nijsten T, Looman CW, Stern RS. Clinical severity of psoriasis in last 20 years of PUVA study. Arch Dermatol 2007;143(9):1113-21.10.1001/archderm.143.9.1113
  3. 3. Ghoreschi K, Weigert C, Röcken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol 2007;25:574-80.10.1016/j.clindermatol.2007.08.012
  4. 4. Davidovici BB, Sattar N, Prinz J, Puig L, Emery P, Barker JN, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010;130(7):1785-96.10.1038/jid.2010.103
  5. 5. Armstrong AW, Callis Duffin K, Garg A, Gelfand JM, Gottlieb AB, Krueger GG, et al. Exploring priority research areas in psoriasis and psoriatic arthritis from dermatologists’ perspective: a report from the GRAPPA 2011: annual meeting. J Rheumatol 2012;39(11):2204-10.10.3899/jrheum.120825
  6. 6. Feinstein AR. Th e pretherapeutic classification of comorbidity in chronic disease. J Chronic Dis 1970;23:455-568.10.1016/0021-9681(70)90054-8
  7. 7. Klein DN, Riso LP. Psychiatric disorders: problems of boundaries and comorbidity. In: Costello CG, editor. Basic issues in psychopathology. New York: Guilford; 1993. p. 19-66.
  8. 8. Pearce DJ, Morrison AE, Higgins KB, Crane MM, Balkrishnan R, Fleischer AB Jr, et al. Th e comorbid state of psoriasis patients in a university dermatology practice. J Dermatol Treat 2005;16(5-6):319-23.10.1080/0954663050033597716428152
  9. 9. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296(14):1735-41.10.1001/jama.296.14.173517032986
  10. 10. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008;159(4):895-902.10.1111/j.1365-2133.2008.08707.x18616778
  11. 11. Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mork C, et al. Self-reported stress reactivity and psoriasisrelated stress of Nordic psoriasis sufferers. J Eur Acad Dermatol Venereol 2004;18(1):27-36.10.1111/j.1468-3083.2004.00721.x14678528
  12. 12. Bhole VM, Choi HK, Burns LC, Vera Kellet C, Lacaille DV, Gladman DD, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford) 2012;51(3):552-6.10.1093/rheumatology/ker349
  13. 13. Cheng J, Kuai D, Zhang L, Yang X, Qiu B. Psoriasis increased the risk of diabetes: a meta-analysis. Arch Dermatol Res 2012;304(2):119-25.10.1007/s00403-011-1200-6
  14. 14. Dreiher J, Weitzman D, Cohen AD. Psoriasis and osteoporosis: a sex-specifi c association? J Invest Dermatol 2009;129(7):1643-9.
  15. 15. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. Th e risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006;126(10):2194-201.10.1038/sj.jid.5700410
  16. 16. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatol Treat. 2008;19(1):5-21.10.1080/09546630701364768
  17. 17. Mussi A, Bonifati C, Carducci M, D`Agosto G, Pimpinelli D, D`Urso D, et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997;11(3):115-8.
  18. 18. Wakkee M, Th io HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profi les in untreated and treated psoriasis patients. Atherosclerosis 2007;190(1):1-9.10.1016/j.atherosclerosis.2006.07.011
  19. 19. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefi ts and risks. Br J Dermatol 2005;52:597-615.10.1111/j.1365-2133.2005.06563.x
  20. 20. Gisondi P, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M, et al. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. J Eur Acad Dermatol Venereol 2013;27(1):e30-41.10.1111/j.1468-3083.2012.04450.x
  21. 21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.10.1016/0021-9681(87)90171-8
  22. 22. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985;13:450-6.10.1016/S0190-9622(85)70188-0
  23. 23. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3(1):55-78.10.1016/0049-0172(73)90035-8
  24. 24. Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97.10.1001/jama.285.19.248611368702
  25. 25. Samarasekera E, Neilson JM, Warren RB, Parnham J, Smith CH. Incidence of cardiovascular disease in people with psoriasis: a systematic review and meta-analysis. J Invest Dermatol In press, doi: 10.1038/jid.2013.149.10.1038/jid.2013.14923528816
  26. 26. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296(14):1735-41.10.1001/jama.296.14.173517032986
  27. 27. Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19(3):225-30.10.1023/B:EJEP.0000020447.59150.f9
  28. 28. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc 2013;2(2):PMID 23447749.10.1161/JAHA.113.000062364727823557749
  29. 29. Stern RS, Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J Invest Dermatol 1988;91(3):197-201.10.1111/1523-1747.ep124648473411140
  30. 30. Jensen P, Th yssen JP, Zachariae C, Hansen PR, Linneberg A, Skov L. Cardiovascular risk factors in subjects with psoriasis: a cross-sectional general population study. Int J Dermatol 2013;52(6):681-3.10.1111/j.1365-4632.2011.05408.x22512330
  31. 31. Maradit-Kremers H, Dierkhising RA, Crowson CS, Icen M, Ernste FC, McEvoy MT. Risk and predictors of cardiovascular disease in psoriasis: a population-based study. Int J Dermatol 2013;52(1):32-40.10.1111/j.1365-4632.2011.05430.x353917023278607
  32. 32. Brauchli YB, Jick SS, Curtin F, Meier CR. Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study. Br J Dermatol 2008;158(6):1299-307.10.1111/j.1365-2133.2008.08563.x18410416
  33. 33. Wakkee M, van der Linden M, Nijsten T. Psoriasis appears not to be directly related with using cardiovascular and antidiabetic drugs. J Invest Dermatol 2008;128:2548.
  34. 34. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and metaanalysis. JAMA Dermatol. 2013;149(1):84-91.10.1001/2013.jamadermatol.40623407990
  35. 35. Cheng J, Kuai D, Zhang L, Yang X, Qiu B. Psoriasis increased the risk of diabetes: a meta-analysis. Arch Dermatol Res 2012;304(2):119-25.10.1007/s00403-011-1200-622210176
  36. 36. Shapiro J, Cohen AD, David M, Hodak E, Chodik G, Viner A, et al. Th e association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007;56(4):629-34.10.1016/j.jaad.2006.09.01717157411
  37. 37. Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol 2008;159(6):1331-7.10.1111/j.1365-2133.2008.08814.x18782318
  38. 38. Cohen AD, Dreiher J, Shapiro Y, Vidavsky L, Vardy DA, Davidovici B, et al. Psoriasis and diabetes: a populationbased cross-sectional study. J Eur Acad Dermatol Venereol 2008;22:585-9.10.1111/j.1468-3083.2008.02636.x18331320
  39. 39. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005;125:61-7.10.1111/j.0022-202X.2005.23681.x15982303
  40. 40. Kim GW, Park HJ, Kim HS, Kim Sh, Ko HC, Kim BS, et al. Analysis of cardiovascular risk factors and metabolic syndrome in korean patients with psoriasis. Ann Dermatol 2012;24(1):11-510.5021/ad.2012.24.1.11328384322363149
  41. 41. International Diabetes Federation [homepage on the Internet], [cited 2013 Jan 18]. Available from: http://www.idf.org.
  42. 42. Gisondi P, Tessari G, Conti A, Piaserico S, Shianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007;157(1):68-73.10.1111/j.1365-2133.2007.07986.x17553036
  43. 43. Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol Venereol Leprol 2010;76(6):662-5.10.4103/0378-6323.7246221079309
  44. 44. Tekin NS, Tekin IO, Barut F, Sipahi EY. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm 2007;2007:ID 78454.10.1155/2007/78454180429717497039
  45. 45. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298(7):321-8.10.1007/s00403-006-0703-z17021763
  46. 46. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55(5):829-35.10.1016/j.jaad.2006.08.04017052489
  47. 47. Gerdes S, Zahl VA, Knopf H, Weichenthal M, Mrowietz U. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 2008;159:1116-23.10.1111/j.1365-2133.2008.08786.x18717681
  48. 48. Minov J, Karadžinska-Bislimovska J, Vasilevska K, Nelovska Z, Risteska-Kuc S, Stoleski S, et al. Smoking among Macedonian workers five years after the anti-smoking campaign. Arh Hig Rada Toksikol 2012;63(2):207-13. 10.2478/10004-1254-63-2012-215022728803
Language: English
Page range: 53 - 64
Published on: Oct 12, 2013
Published by: Serbian Association of Dermatovenereologists (SAD)
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2013 Katerina Damevska, Lence Neloska, Gjeorgji Gocev, Marija Mihova, published by Serbian Association of Dermatovenereologists (SAD)
This work is licensed under the Creative Commons License.